摘要
目的：利用Meta分析方法探讨阿罗洛尔治疗原发性高血压的有效性及安全性。方法：计算机检索Cochrane图书馆临床对照试验资料库（2008年第3期）、MEDLINE（1991—2009年3月）、EMbase（1991年1月—2009年3月）、CBMdisc（1991年1月—2009年3月）、CNKI（1994年1月—2009年3月）以及手工检索关于阿罗洛尔治疗原发性高血压的相关文献,在严格质量评价的基础上,应用RevMan 4.2软件对数据进行Meta分析。结果：共初检出176篇文献,经筛选最终纳入6篇8项关于阿罗洛尔与其他常用抗高血压药治疗原发性高血压的文献。同质性检验,有效性：χ^2=4.41,df=7,P=0.73;安全性：χ^2=2.96,df=4,P=0.56。二者合并效应量的估计,有效性：Z=0.64（P=0.52）,合并OR=1.17,OR95%CI（0.72-1.85）;安全性：Z=1.75（P=0.08）,合并OR=0.60,OR95%CI（0.34-1.06）。结论：阿罗洛尔治疗原发性高血压与对照组比较具有相似的有效性及安全性。
Objective To approach the efficacy and safety of arotinolol in treating essential hypertension. Methods The studies about arotinolol in treating essential hypertension were accessed by searching the Cochrane Central Register of Controlled Trials （Issue 3, 2008）, MEDLINE （1991 to March 2009）, EMbase （1991 to March 2009）, CBMdisc （1991 to March 2009）, and CNKI （1994 to March 2009）. The relevant journals and conference proceedings also hand searched. Randomized controlled trials （RCTs） in which arotinolol was used to treat patients with essential hypertension were collected. Then the retrieved studies according to predefined inclusion and exclusion criteria were screened, the quality of included studies was evaluated, and Meta analysis was performed by using RevMan 4. 2 software. Results A total of 176 articles were found and 6 of which were finally included. In homogeneity test： χ^2=4.41, df=7, P=0. 73 （efficacy） ;χ^2 =2. 96, df=4, P=0. 56 （safety） . In combined test , Z=0.64 （P=0.52）, OR=1.17, OR95%CI （0.72--1.85） （efficacy）; Z=1.75 （P=0.08）, OR=0.60, OR95%CI （0.34--1.06） （safety）. Conclusion There is no significant difference in efficacy and safety between arotinolol and control group in treating essential hypertension.
出处
《吉林大学学报（医学版）》
CAS
CSCD
北大核心
2009年第5期949-954,共6页
Journal of Jilin University：Medicine Edition
基金
吉林省科技厅科研基金资助课题(20050408)
